T A Zesiewicz

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 336112, USA
    Mov Disord 20:1205-9. 2005
  2. ncbi Levetiracetam-induced parkinsonism in a Huntington disease patient
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA
    Clin Neuropharmacol 28:188-90. 2005
  3. ncbi Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14)
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, FL 34677, USA
    Clin Neuropharmacol 31:363-5. 2008
  4. ncbi A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:1660-3. 2007
  5. ncbi Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, FL, USA
    Clin Rheumatol 27:389-90. 2008
  6. ncbi The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:106-11. 2006
  7. ncbi Topiramate-induced psychosis in patients with essential tremor: report of 2 cases
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:168-9. 2006
  8. ncbi Social Security Disability Insurance (SSDI) in Parkinson's disease
    T A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Disabil Rehabil 29:1934-6. 2007
  9. ncbi Pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Neuroscience Program, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:139-41. 2007
  10. ncbi Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 32:48-50. 2009

Detail Information

Publications50

  1. ncbi Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 336112, USA
    Mov Disord 20:1205-9. 2005
    ..There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak-dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia...
  2. ncbi Levetiracetam-induced parkinsonism in a Huntington disease patient
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA
    Clin Neuropharmacol 28:188-90. 2005
    ..Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline...
  3. ncbi Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14)
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, FL 34677, USA
    Clin Neuropharmacol 31:363-5. 2008
    ..Two patients with spinocerebellar ataxia (types 3 and 14) experienced marked improvement in their cerebellar symptoms shortly after taking varenicline (Chantix)...
  4. ncbi A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:1660-3. 2007
    ..PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET...
  5. ncbi Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, FL, USA
    Clin Rheumatol 27:389-90. 2008
    ..The chorea lasted for a year and resolved completely within 2 weeks of discontinuing gabapentin...
  6. ncbi The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:106-11. 2006
    ..In patients with low or low-normal folate levels, levodopa administration is associated with a greater increase in homocysteine and concomitant entacapone administration is associated with a greater reduction in homocysteine...
  7. ncbi Topiramate-induced psychosis in patients with essential tremor: report of 2 cases
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 29:168-9. 2006
    ..All adverse symptoms resolved several days after topiramate was discontinued...
  8. ncbi Social Security Disability Insurance (SSDI) in Parkinson's disease
    T A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Disabil Rehabil 29:1934-6. 2007
    ..We performed a descriptive pilot study that examined PD patients' experience with SSDI...
  9. ncbi Pregabalin (Lyrica) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Neuroscience Program, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:139-41. 2007
    ..Both patients also reported moderate reduction in tremor on the Clinical Global Impression Scale, and Fahn-Tolosa-Marin Part I scores were markedly improved...
  10. ncbi Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, 33612, USA
    Clin Neuropharmacol 32:48-50. 2009
    ..The severe bradykinesia and rigidity persisted despite reactivation of the deep brain stimulator and immediate reinstitution of Parkinson disease medications, but resolved completely several hours after discontinuation of fentanyl...
  11. ncbi A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 22:279-82. 2007
    ..ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry...
  12. ncbi Depression in Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida College of Medicine, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Psychiatry Rep 4:69-73. 2002
    ..This information may help guide clinical treatment and define the need for further studies...
  13. ncbi Management of essential tremor
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Harborside Medical Tower, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA
    Curr Neurol Neurosci Rep 2:324-30. 2002
    ..In patients with medically refractory tremor, alternative therapies, including surgery or injections of botulinum toxin, may be considered...
  14. ncbi Clozapine withdrawal symptoms in a Parkinson's disease patient
    Theresa A Zesiewicz
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Mov Disord 17:1365-7. 2002
    ..Clozapine should be gradually withdrawn over a period of 1 to 2 weeks when possible, and abruptly discontinued only when necessary...
  15. ncbi Driving safety in Parkinson's disease
    T A Zesiewicz
    Department of Neurology, University of South Florida, Tampa, USA
    Neurology 59:1787-8. 2002
    ..7, p < 0.01). In PD patients, collisions were associated with Hoehn and Yahr stage (chi(2) = 12.4, p = 0.006) and correlated with Unified Parkinson's Disease Rating Scale score (r = 0.5, p < 0.01)...
  16. ncbi Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:1998-2001. 2006
    ..6 +/- 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop-out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients...
  17. ncbi Substantial improvement in a Meige's syndrome patient with levetiracetam treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    Mov Disord 19:1518-21. 2004
    ..This report and data from an animal model of paroxysmal dystonia suggest that LEV might be helpful in the treatment of dystonia...
  18. ncbi Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology
    T A Zesiewicz
    Department of Neurology, Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, USA
    Neurology 64:2008-20. 2005
    ..Additional prospective, double-blind, placebo-controlled trials are needed to better determine the efficacy and side effects of pharmacologic and surgical treatments of ET...
  19. ncbi Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology
    T A Zesiewicz
    University of South Florida, Tampa, USA
    Neurology 77:1752-5. 2011
    ..This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET)...
  20. ncbi Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
    W G Ondo
    Department of Neurology, University of Texas Health Science Center, Houston, TX, USA
    Neurology 78:1650-4. 2012
    ..To evaluate the efficacy and tolerability of lubiprostone (Amitiza) for constipation in Parkinson disease (PD) in a double-blind, randomized, controlled study...
  21. ncbi A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3
    T A Zesiewicz
    Department of Neurology, Ataxia Research Center, University of South Florida, Tampa, USA
    Neurology 78:545-50. 2012
    ....
  22. ncbi Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome
    T A Zesiewicz
    Parkinson Research Foundation Center of Excellence at University of South Florida, University of South Florida, Tampa, FL 34677, USA
    Acta Neurol Scand 119:135-8. 2009
    ..Varenicline was started as part of a smoking cessation program...
  23. ncbi Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey
    T A Zesiewicz
    Department of Neurology, University of South Florida, 12901 Bruce B. Downs Blvd MDC 55, Tampa, FL 33612, USA
    Parkinsonism Relat Disord 10:417-20. 2004
    ..CONCLUSIONS: In this cross-sectional study of a national Medicare database, heart failure occurred twice as frequently in elderly PD patients as in non-PD patients. Prospective studies are warranted to verify these findings...
  24. ncbi Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology
    T A Zesiewicz
    University of South Florida, Tampa, USA
    Neurology 74:924-31. 2010
    ..Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were previously reviewed as part of American Academy of Neurology practice parameters and were not included here...
  25. ncbi Advances in the pharmacologic management of early Parkinson disease
    Robert A Hauser
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Neurologist 13:126-32. 2007
    ..However, the disease continues to progress, and the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesias...
  26. ncbi Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center, University of South Florida, Tampa, Florida 33612, USA
    Curr Neurol Neurosci Rep 7:302-10. 2007
    ..Deep brain stimulation of the subthalamic nucleus is now the most commonly used surgical procedure for PD patients, and it is very effective in treating LID...
  27. ncbi Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease
    Theresa A Zesiewicz
    Department of Neurology, University of South Florida, Tampa, 33612, USA
    CNS Drugs 23:817-35. 2009
    ..Whenever possible, clinicians should ensure that complementary therapy is used appropriately in PD patients without reducing the benefits of dopaminergic therapy...
  28. ncbi Reduction of circulating endothelial cells in peripheral blood of ALS patients
    Svitlana Garbuzova-Davis
    Center of Excellence for Aging and Brain Repair, College of Medicine, University of South Florida, Tampa, Florida, United States of America
    PLoS ONE 5:e10614. 2010
    ..Since circulating endothelial cells (CECs) in the peripheral blood are associated with endothelium damage, being detached dysfunctional endothelial cells, we hypothesized that CEC levels may reflect endothelium condition in ALS patients...
  29. ncbi Nonmotor symptoms of Parkinson's disease
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, 12901 Bruce B Downs Blvd, MDC Box 55, Tampa, FL 33612, USA
    Expert Rev Neurother 6:1811-22. 2006
    ..A new screening questionnaire and the revised Unified PD Rating Scale should assist healthcare providers to better identify and evaluate these symptoms. This article reviews the identification and treatment of nonmotor symptoms in PD...
  30. ncbi Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix)
    Theresa A Zesiewicz
    Department of Neurology, University of South Florida Ataxia Research Center, Tampa, FL 33612, USA
    J Clin Neuromuscul Dis 10:191-3. 2009
    ....
  31. ncbi Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
    Kelly L Sullivan
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, Florida 33612, USA
    Mov Disord 21:115-6. 2006
    ..There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS)...
  32. ncbi Essential tremor. Epidemiology, diagnosis, and treatment
    Kelly L Sullivan
    Department of Neurology, Parkinson's Disease and Movement Disorders Center, Tampa General Hospital Healthcare, University of South Florida, Tampa, Florida 33612, USA
    Neurologist 10:250-8. 2004
    ..Additional studies are also needed to determine the best treatment of head and voice tremor with pharmacologic and surgical interventions. With proper treatment, tremor is sufficiently reduced in the majority of patients...
  33. ncbi Clinical trials aimed at detecting neuroprotection in Parkinson's disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida, USA
    Neurology 66:S58-68. 2006
    ..Better methods of assessing putative neuroprotection in PD are needed...
  34. ncbi Neurosurgery for Parkinson's disease
    T A Zesiewicz
    Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa 33606, USA
    Semin Neurol 21:91-101. 2001
    ..This chapter reviews the history of surgical procedures for PD, describes current procedures, and offers a look into the future of neurosurgical options for PD...
  35. ncbi Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations
    Alberto J Espay
    Department of Neurology, The Neuroscience Institute, Movement Disorders Center, University of Cincinnati, Cincinnati, Ohio 45267 0525, USA
    Mov Disord 23:2357-62. 2008
    ..Further efficacy studies on chronic stimulation to disrupt the abnormal oscillatory activity in this disorder are warranted...
  36. ncbi Phenomenology and treatment of tremor disorders
    T A Zesiewicz
    Parkinson's Disease and Movement Disorders Center, Department of Neurology, Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA
    Neurol Clin 19:651-80, vii. 2001
    ..Accurate diagnosis is a critical factor in predicting the natural history and response to treatment...
  37. ncbi Chorea in a patient with cerebral palsy: treatment with levetiracetam
    Maria V Recio
    Department of Neurology, University of South Florida, Tampa, FL 33612, USA
    Mov Disord 20:762-4. 2005
    ..We report on the case of an adult cerebral palsy patient who developed severe chorea coincident with a febrile illness from a nonstreptococcal infection. The chorea improved markedly with the use of levetiracetam (LEV, Keppra)...
  38. ncbi Levetiracetam for the treatment of generalized dystonia
    Kelly L Sullivan
    Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, FL 33612, USA
    Parkinsonism Relat Disord 11:469-71. 2005
    ..Improvements were noted in blepharospasm, cervical, and truncal dystonia. The patient has been on LEV for a total of 20 weeks, and has experienced sustained improvement of symptoms...
  39. ncbi Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?
    Theresa A Zesiewicz
    Parkinson s Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa General Healthcare, Tampa, Florida 33606, USA
    CNS Drugs 17:593-600. 2003
    ..Patients with Parkinson's disease and caregivers should be informed about the risk of sleepiness and sleep attacks associated with dopaminergic medications and the potential implications for driving safety...
  40. ncbi Use of nutritional supplements in Parkinson's disease patients
    Summer C Wolfrath
    Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, and Department of Neurology, College of Medicine, University of South Florida, Tampa, Florida, USA
    Mov Disord 21:1098-101. 2006
    ..Greater awareness of nutritional supplement use in PD patients is warranted to avoid potentially harmful effects and drug interactions...
  41. ncbi Levetiracetam for stiff-person syndrome: report of 2 patients
    W Reed Shimberg
    Parkinson s Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA
    Clin Neuropharmacol 31:301-2. 2008
    ..We report 2 patients with stiff-person syndrome whose spasms were greatly relieved by levetiracetam (Keppra)...
  42. ncbi Levetiracetam for the treatment of essential tremor
    Kelly L Sullivan
    Mov Disord 20:640. 2005
  43. ncbi Zonisamide-induced mania in an essential tremor patient
    Kelly L Sullivan
    J Clin Psychopharmacol 26:439-40. 2006
  44. ncbi Chorea induced by lamotrigine
    Theresa A Zesiewicz
    J Child Neurol 21:357; author reply 357-8. 2006
  45. ncbi Tiagabine and exacerbation of essential tremor
    Theresa A Zesiewicz
    Mov Disord 22:2132-3. 2007
  46. ncbi Low-dose topiramate (topamax) in the treatment of essential tremor
    Theresa A Zesiewicz
    Clin Neuropharmacol 30:247-8. 2007
  47. ncbi Treatment of chorea with levetiracetam
    Theresa A Zesiewicz
    Eur J Clin Pharmacol 62:87. 2006
  48. ncbi Prevalence and treatment of non-motor symptoms in Parkinson's disease
    Kelly L Sullivan
    Parkinsonism Relat Disord 13:545. 2007
  49. ncbi Vascular hemichorea/hemiballismus and topiramate
    Theresa A Zesiewicz
    Mov Disord 21:581; author reply 582. 2006
  50. ncbi Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation
    Theresa A Zesiewicz
    Eur Neurol 59:187-9. 2008